Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.51)
# 293
Out of 5,182 analysts
90
Total ratings
58.75%
Success rate
20.58%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $110 → $121 | $98.51 | +22.83% | 5 | Apr 15, 2026 | |
| BIIB Biogen | Maintains: Hold | $193 → $189 | $180.67 | +4.61% | 7 | Apr 13, 2026 | |
| TERN Terns Pharmaceuticals | Downgrades: Hold | $56 → $53 | $52.95 | +0.09% | 5 | Mar 31, 2026 | |
| IVA Inventiva | Initiates: Buy | $13 | $5.13 | +153.41% | 1 | Mar 19, 2026 | |
| SEPN Septerna | Maintains: Buy | $34 → $35 | $25.07 | +39.64% | 2 | Mar 11, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $46.29 | +18.82% | 6 | Mar 4, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $61.60 | +49.35% | 5 | Feb 3, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $86.68 | +33.83% | 6 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $520.09 | +23.06% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $95.72 | -2.84% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $14.81 | +1.28% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $31.97 | +56.40% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $744.44 | +9.08% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $10.29 | +6.90% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $11.01 | +127.07% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $868.27 | +19.55% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $197.38 | +9.94% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $26.79 | +19.45% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $30.64 | +63.19% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.73 | +3,021.39% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.54 | +170.76% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.49 | +118.31% | 1 | Jul 31, 2024 |
Protagonist Therapeutics
Apr 15, 2026
Maintains: Buy
Price Target: $110 → $121
Current: $98.51
Upside: +22.83%
Biogen
Apr 13, 2026
Maintains: Hold
Price Target: $193 → $189
Current: $180.67
Upside: +4.61%
Terns Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: $56 → $53
Current: $52.95
Upside: +0.09%
Inventiva
Mar 19, 2026
Initiates: Buy
Price Target: $13
Current: $5.13
Upside: +153.41%
Septerna
Mar 11, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $25.07
Upside: +39.64%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $46.29
Upside: +18.82%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $61.60
Upside: +49.35%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $86.68
Upside: +33.83%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $520.09
Upside: +23.06%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $95.72
Upside: -2.84%
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $14.81
Upside: +1.28%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $31.97
Upside: +56.40%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $744.44
Upside: +9.08%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $10.29
Upside: +6.90%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $11.01
Upside: +127.07%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $868.27
Upside: +19.55%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $197.38
Upside: +9.94%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.79
Upside: +19.45%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $30.64
Upside: +63.19%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.73
Upside: +3,021.39%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.54
Upside: +170.76%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $16.49
Upside: +118.31%